Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIM-531 as Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors
NCT06425926Phase 2Recruiting
- Sponsor
- Georgiamune
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GIM-531 in solid tumor, melanoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), ovarian cancer, sponsored by Georgiamune. Started May 2024; status: recruiting.
02
Drugs
GIM-531
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)ovarian cancer
Beyond the preview
Go deeper on NCT06425926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425926.